Medical Market Report

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market By Type (Exenatied , Liraglutide , Lixisenatide , and Others), By Application (Hospital , and Pharmacy), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • 134276
  • 12-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    The report on Glucagon Like Peptide-1 (GLP-1) Agonists Market offers in-depth analysis on market trends, drivers, restraints, opportunities etc. Along with qualitative information, this report include the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. for the forecast years. The global glucagon like peptide-1 (glp-1) agonists market is segmented on the basis of Type, Application and geography.

    The worldwide market for Glucagon Like Peptide-1 (GLP-1) Agonists Market is expected to grow at a CAGR of roughly x.x% over the next ten years and will reach US$ XX.X Mn in 2028, from US$ XX.X Mn in 2018, according to a new Market.us (Prudour Research) study.

    Glucagon Like Peptide-1 (GLP-1) Agonists Market Scope:

    By type, the market is segmented into Exenatied, Liraglutide, Lixisenatide, Albiglutide and Dulaglutide. By Application, the market is divided into Hospital and Pharmacy. Based on geography, market is analyzed across North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. Major players profiled in the report include Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi, Bristol-Myers Squibb and Amylin.

    Key Market Segments

    Type

    Exenatied
    Liraglutide
    Lixisenatide
    Albiglutide
    Dulaglutide

    Application

    Hospital
    Pharmacy

    Key Market Players included in the report:

    Novo Nordisk
    AstraZeneca
    Eli Lilly
    GSK
    Sanofi
    Bristol-Myers Squibb
    Amylin

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and Glucagon Like Peptide-1 (GLP-1) Agonists Market share analysis of high players, along with company profiles and which collectively include about the fundamental opinions regarding the market landscape. Emerging and high-growth sections of Glucagon Like Peptide-1 (GLP-1) Agonists Market, high-growth regions, and market drivers, restraints and also market chances.
    The analysis covers Glucagon Like Peptide-1 (GLP-1) Agonists Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Glucagon Like Peptide-1 (GLP-1) Agonists Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the Glucagon Like Peptide-1 (GLP-1) Agonists Market together side their company profiles, SWOT analysis, latest advancements and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers and industry-specific challenges and risks).
    To know the Glucagon Like Peptide-1 (GLP-1) Agonists Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of Glucagon Like Peptide-1 (GLP-1) Agonists sub-markets, depending on key regions (various vital states).
    To analyze Glucagon Like Peptide-1 (GLP-1) Agonists Market concerning growth trends, prospects and also their participation in the entire sector.
    To examine and study the Glucagon Like Peptide-1 (GLP-1) Agonists Market size (volume & value) from the company, essential regions/countries, products and Application, background information from 2012 to 2018 and also prediction to 2028.
    Primary worldwide Glucagon Like Peptide-1 (GLP-1) Agonists Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches and acquisitions on the market.

  • Table Of Content 
    1. Glucagon Like Peptide-1 (GLP-1) Agonists Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope2. Executive Summary
    

    2.1. Key Findings by Major Segments
    
2.2. Top strategies by Major Players3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview
    

    3.1. Glucagon Like Peptide-1 (GLP-1) Agonists Market Dynamics
    

    3.1.1. Drivers
    
3.1.2. Opportunities
    
3.1.3. Restraints
    
3.1.4. Challenges3.2. PESTLE Analysis
    
3.3. Opportunity Map Analysis
    
3.4. PORTER’S Five Forces Analysis
    
3.5. Market Competition Scenario Analysis
    
3.6. Product Life Cycle Analysis
    
3.7. Opportunity Orbits
    
3.8. Manufacturer Intensity Map4. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

    4.1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis by Type: Introduction
    
4.2. Market Size and Forecast by Region
    
4.3. Exenatied
    
4.4. Liraglutide
    
4.5. Lixisenatide
    
4.6. Albiglutide
    
4.7. Dulaglutide5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

    5.1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis by Application: Introduction
    
5.2. Market Size and Forecast by Region
    
5.3. Hospital
    
5.4. Pharmacy6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

    6.1. North America
    

    6.1.1. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market: Regional Trend Analysis
    

    6.1.1.1. US
    
6.1.1.2. Canada
    
6.1.1.3. Mexico
    

    6.2. Europe
    

    6.2.1. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market: Regional Trend Analysis
    

    6.2.1.1. Germany
    
6.2.1.2. France
    
6.2.1.3. UK
    
6.2.1.4. Russia
    
6.2.1.5. Italy
    
6.2.1.6. Rest of Europe
    

    6.3. Asia-Pacific
    

    6.3.1. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market: Regional Trend Analysis
    

    6.3.1.1. China
    
6.3.1.2. Japan
    
6.3.1.3. Korea
    
6.3.1.4. India
    
6.3.1.5. Rest of Asia
    

    6.4. Latin America
    

    6.4.1. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market: Regional Trend Analysis
    

    6.4.1.1. Brazil
    
6.4.1.2. Argentina
    
6.4.1.3. Rest of Latin America
    

    6.5. Middle East and Africa
    

    6.5.1. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market: Regional Trend Analysis
    

    6.5.1.1. GCC
    
6.5.1.2. South Africa
    
6.5.1.3. Israel
    
6.5.1.4. Rest of MEA
    
7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

    7.1. Market Share Analysis
    
7.2. Company Profiles
    
7.3. Novo Nordisk
    

    7.3.1. Company Overview
    
7.3.2. Financial Highlights
    
7.3.3. Product Portfolio
    
7.3.4. SWOT Analysis
    
7.3.5. Key Strategies and Developments7.4. AstraZeneca
    

    7.4.1. Company Overview
    
7.4.2. Financial Highlights
    
7.4.3. Product Portfolio
    
7.4.4. SWOT Analysis
    
7.4.5. Key Strategies and Developments7.5. Eli Lilly
    

    7.5.1. Company Overview
    
7.5.2. Financial Highlights
    
7.5.3. Product Portfolio
    
7.5.4. SWOT Analysis
    
7.5.5. Key Strategies and Developments7.6. GSK
    

    7.6.1. Company Overview
    
7.6.2. Financial Highlights
    
7.6.3. Product Portfolio
    
7.6.4. SWOT Analysis
    
7.6.5. Key Strategies and Developments7.7. Sanofi
    

    7.7.1. Company Overview
    
7.7.2. Financial Highlights
    
7.7.3. Product Portfolio
    
7.7.4. SWOT Analysis
    
7.7.5. Key Strategies and Developments7.8. Bristol-Myers Squibb
    

    7.8.1. Company Overview
    
7.8.2. Financial Highlights
    
7.8.3. Product Portfolio
    
7.8.4. SWOT Analysis
    
7.8.5. Key Strategies and Developments7.9. Amylin
    

    7.9.1. Company Overview
    
7.9.2. Financial Highlights
    
7.9.3. Product Portfolio
    
7.9.4. SWOT Analysis
    
7.9.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.